Original article: Soni M. Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection. Int J Lab Hematol. 2020;00:1-5. https://doi.org/10.1111/ijlh.13425.
作者信息
van Duijnhoven Hans L P, Leuvenink Jacqueline, Keuren Jeffrey F W
机构信息
Department of Clinical Chemistry and Hematology, Elkerliek Ziekenhuis, Helmond, The Netherlands.
Department of Clinical Chemistry and Hematology, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, The Netherlands.
出版信息
Int J Lab Hematol. 2021 Dec;43(6):e287-e289. doi: 10.1111/ijlh.13572. Epub 2021 May 11.
Abstract
摘要
相似文献
1
Original article: Soni M. Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection. Int J Lab Hematol. 2020;00:1-5. https://doi.org/10.1111/ijlh.13425.原始文章：索尼·M. 嗜酸性粒细胞减少作为新冠病毒感染的诊断和预后指标的评估。《国际实验室血液学杂志》。2020年；00:1 - 5。https://doi.org/10.1111/ijlh.13425 。
Int J Lab Hematol. 2021 Dec;43(6):e287-e289. doi: 10.1111/ijlh.13572. Epub 2021 May 11.
2
Original Article: Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection.原创文章：评估嗜酸性粒细胞减少作为新型冠状病毒肺炎感染的诊断和预后指标
Int J Lab Hematol. 2021 Dec;43(6):e303. doi: 10.1111/ijlh.13573. Epub 2021 May 11.
3
Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection.评价嗜酸性粒细胞减少症作为 COVID-19 感染的诊断和预后指标。
Int J Lab Hematol. 2021 Jul;43 Suppl 1:137-141. doi: 10.1111/ijlh.13425. Epub 2020 Dec 8.
4
Eosinopenia <100/μL as a marker of active COVID-19: An observational prospective study.嗜酸性粒细胞计数 <100/μL 作为 COVID-19 活动期的标志物：一项观察性前瞻性研究。
J Microbiol Immunol Infect. 2021 Feb;54(1):61-68. doi: 10.1016/j.jmii.2020.12.005. Epub 2021 Jan 8.
5
Eosinopenia in COVID-19: What we missed so far?新冠病毒肺炎中的嗜酸性粒细胞减少症：我们目前遗漏了什么？
J Microbiol Immunol Infect. 2021 Oct;54(5):1006-1007. doi: 10.1016/j.jmii.2021.01.013. Epub 2021 Feb 18.
6
Eosinopenia could be a relevant prognostic biomarker in patients with coronavirus disease 2019.嗜酸性粒细胞减少可能是2019冠状病毒病患者的一个相关预后生物标志物。
Allergy Asthma Proc. 2020 Nov 1;41(6):e80-e82. doi: 10.2500/aap.2020.41.200079.
7
EOSINOPENIA: an early, effective and relevant COVID-19 biomarker?嗜酸性粒细胞减少：一种早期、有效的新冠病毒相关生物标志物？
QJM. 2021 Feb 18;114(1):68-69. doi: 10.1093/qjmed/hcaa259.
8
Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia.嗜酸性粒细胞减少症是 COVID-19 肺炎患者严重疾病和不良预后的可靠标志物。
Int J Clin Pract. 2021 Jul;75(7):e14047. doi: 10.1111/ijcp.14047. Epub 2021 Feb 5.
9
Behavior of Eosinophil Counts in Recovered and Deceased COVID-19 Patients over the Course of the Disease.新冠肺炎患者疾病过程中恢复期和死亡患者嗜酸性粒细胞计数的变化。
Viruses. 2021 Aug 24;13(9):1675. doi: 10.3390/v13091675.
10
The Systemic Immune Response in COVID-19 Is Associated with a Shift to Formyl-Peptide Unresponsive Eosinophils.COVID-19 中的系统性免疫反应与向无反应性甲酰肽的嗜酸性粒细胞转移有关。
Cells. 2021 May 5;10(5):1109. doi: 10.3390/cells10051109.
本文引用的文献
1
Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection.评价嗜酸性粒细胞减少症作为 COVID-19 感染的诊断和预后指标。
Int J Lab Hematol. 2021 Jul;43 Suppl 1:137-141. doi: 10.1111/ijlh.13425. Epub 2020 Dec 8.
2
False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications.新型冠状病毒2型感染的假阴性检测——挑战与影响
N Engl J Med. 2020 Aug 6;383(6):e38. doi: 10.1056/NEJMp2015897. Epub 2020 Jun 5.
3
Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series.中国浙江 91 例 COVID-19 住院患者的流行病学和临床特征：一项回顾性、多中心病例系列研究。
QJM. 2020 Jul 1;113(7):474-481. doi: 10.1093/qjmed/hcaa089.
4
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.中国武汉 140 名 SARS-CoV-2 感染患者的临床特征。
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
Zotero 插件